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Abstract
Background:  The Alberta Kidney Disease Network is a collaborative nephrology research
organization based on a central repository of laboratory and administrative data from the Canadian
province of Alberta.
Description: The laboratory data within the Alberta Kidney Disease Network can be used to
define patient populations, such as individuals with chronic kidney disease (using serum creatinine
measurements to estimate kidney function) or anemia (using hemoglobin measurements). The
administrative data within the Alberta Kidney Disease Network can also be used to define cohorts
with common medical conditions such as hypertension and diabetes. Linkage of data sources
permits assessment of socio-demographic information, clinical variables including comorbidity, as
well as ascertainment of relevant outcomes such as health service encounters and events, the
occurrence of new specified clinical outcomes and mortality.
Conclusion:  The unique ability to combine laboratory and administrative data for a large
geographically defined population provides a rich data source not only for research purposes but
for policy development and to guide the delivery of health care. This research model based on
computerized laboratory data could serve as a prototype for the study of other chronic conditions.
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Background
The Alberta Kidney Disease Network (AKDN) is a collab-
orative group of nephrology researchers located in Calgary
and Edmonton, Alberta, Canada, with a mission to under-
take clinical research and offer research training in kidney
disease. The flagship initiative of the AKDN is a unique
data collection initiative of routine laboratory tests on all
patients in the province of Alberta, resulting in a geo-
graphically inclusive database. Patients identified from
laboratory data are linked to administrative and other
computerized sources to obtain detailed information
including socio-demographic data, clinical data including
comorbidities, health care encounters, health care costs,
death, and kidney-related outcomes.
As the initiative grows the AKDN research findings and
activities are beginning to appear more frequently in peer-
reviewed literature and health policy circles [1-3]. How-
ever, a detailed description of the network's objectives,
details of the laboratory database and linked data sources,
as well as the process for ongoing patient data collection
has not been published. This paper provides such a
description, and includes examples of research under-
taken as well as future research opportunities for the
AKDN.
Objectives of the AKDN
The AKDN objectives are focused around key research
methodologies: clinical epidemiology; health services
research; clinical trials; systematic review and meta-analy-
sis; and health economics. Five specific aims relevant to
the AKDN dataset were initially identified:
1. To determine the prevalence and identify those at
high risk for chronic kidney disease in Alberta, Can-
ada.
2. To determine rates of progression of chronic kidney
disease.
3. To determine if access to/quality of specialized med-
ical care and/or rates of progression of kidney disease
differs by gender, age, location of residence or ethnic
background.
4. To determine the health care costs of caring for
patients with chronic kidney disease.
5. To determine optimal treatments for patients with
chronic kidney disease.
This is not an exhaustive list, and as the Network grows
more objectives and research questions are being
addressed. The examples of on-going research projects
outlined below demonstrate the potential of this data
source.
The AKDN has also developed a plan to facilitate imple-
mentation of its research findings. These knowledge trans-
lation activities target patients, health care providers,
researchers and health policy-makers. These activities aim
to provide information to patients regarding kidney func-
tion and disease in general, health care providers to assist
with investigation and management of patients with
chronic kidney disease, and policy makers to guide evalu-
ation and planning of health service delivery for patients
with chronic kidney disease. A website http://
www.AKDN.info was established to facilitate knowledge
translation activities, as well as to provide information
regarding team members, training opportunities and
research activities.
Construction and Content
Laboratory Database Overview
The core component of the AKDN database is the central
repository of laboratory data. Through the AKDN, and in
collaboration with laboratories across the province of
Alberta (population 3.5 million), we have developed a
process for retrieval, storage and maintenance of compu-
terized laboratory data and relevant laboratory tests for all
patients who have these measurements obtained through-
out the province. To permit complete collection of specific
tests, and in accordance with privacy laws and ethics
board regulations, we were required to limit the number
of laboratory tests retrieved and maintained in the data-
base. As such we selected tests which are routinely ordered
for patients with common medical conditions to guide
ongoing patient assessment, monitor disease progression
and identify relevant outcomes (Table 1). The data ele-
ments (Table 2) include, in addition to details of the test,
Table 1: Laboratory tests collected within the AKDN database
Serum Tests:
Creatinine
Hemoglobin
Potassium
Hemoglobin A1C
Fasting total cholesterol
Fasting high density lipoprotein
Fasting low density lipoprotein
Urine Tests:
Urine dipstick
Urine microalbumin-creatinine ratio
Urine protein-creatinine ratio
24 hour urine proteinBMC Nephrology 2009, 10:30 http://www.biomedcentral.com/1471-2369/10/30
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a unique patient identifier used for linkage with other
data sources. Location of the test (in-versus out-patient) is
important to differentiate test results obtained during a
hospitalization (potentially influenced by an acute ill-
ness), from those obtained in the out-patient setting
(which may better reflect stable medical conditions).
Measurement of kidney function
The serum creatinine is used to obtain an estimate of
glomerular filtration rate (eGFR). Serum creatinine meas-
urements < 25 umol/L are excluded as they are physiolog-
ically implausible. We initially used the non-isotope
dilution mass spectrometry traceable 4-variable Modifica-
tion of Diet in Renal Disease (MDRD) Study equation [4]
to estimate GFR, however beginning in 2003 Alberta lab-
oratories began transitioning to methods for creatinine
analysis calibrated against an isotope dilution mass spec-
trometry (IDMS) reference standard. For these creatinine
measurements the new version of the MDRD formula
derived for use with isotope dilution mass spectrometry
traceable creatinine measurements is used [5]. The linear
relationship between the old and new methods for esti-
mating GFR was established, thus ensuring accuracy of
estimates with these changes in methods over time. To
reduce inter-laboratory variation in eGFR creatinine meas-
urements are standardized across provincial laboratories
to an IDMS reference standard, and a laboratory-specific
correction factor is applied where necessary. Furthermore,
we have previously reported minimal intra-laboratory var-
iation of eGFR estimates over time [6]. Although data on
race is not available, misclassification of eGFR is expected
to be minimal as < 1% of the Alberta population includes
individuals of black race [7].
To reduce the effect of regression to the mean, a statistical
phenomenon that occurs when repeated measurements
with wide variability are made on the same subject [8],
baseline kidney function (index eGFR) is estimated using
all out-patient serum creatinine measurements taken
within a six-month period of the first creatinine measure-
ment, with the index eGFR defined as the mean of the
measurements in this six-month period. The date of the
last serum creatinine measurement in the six month
period, for subjects with more than a single measurement,
is used as the index date. Other definitions of baseline kid-
ney function however can be employed, depending on the
objectives of the particular study.
Proteinuria, an important predictor of outcomes for
patients with kidney disease, is captured by qualitative
(urine dipstick) as well as quantitative measures (Table 1).
There is considerable variation in guidelines as to the
threshold to define clinical significant proteinuria. Our
Table 2: Data elements in the AKDN laboratory component of 
the database
Data elements:
Unique patient identifier
Patient date of birth
Patient gender
Test name
Test result
Test date
Health region
Location of test (in- or out-patient)
Table 3: Classification of urinary albumin and protein concentration
Classification Urine 
albumin:creatinine 
ratio
(mg/mmol)
Urine 
protein:creatinine 
ratio
(mg/mmol)
24 hour urine 
microalbumin
(mg/day)
24 hour urine 
protein
(mg/day)
Urine dipstick
Normal ≤ 2.5 men
≤ 3.5 women
< 15 ≤ 30.0 < 150.0 Negative
Microalbuminuria/
Minimal proteinuria
2.6-29.9 men
3.6-29.9 women
15.0-49.9 31.0-299.9 150.0-299.9 Trace
Macroalbuminuria/
Proteinuria
30.0-69.9 50.0-99.9 300.0-699.9 300.0-999.9 1+
Heavy 
macroalbuminuria/
Heavy proteinuria
70.0-315.9 100.0-450.9 700.0-2449.9 1000.0-3499.9 2+
Nephrotic range > = 316 ≥ 451.0 ≥ 2450.0 ≥ 3500.0 3+
Adapted from Lamb EJ et al [9].BMC Nephrology 2009, 10:30 http://www.biomedcentral.com/1471-2369/10/30
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current approach to categorizing urinary protein concen-
tration (Table 3) is based on that proposed by Lamb et
al[9].
Linked Data Sources
Linkage of laboratory data to administrative and other
computerized data sources provides a rich source of infor-
mation for assessment of socio-demographic characteris-
tics, clinical variables and health outcomes (Figure 1). The
unique patient identifier is used to link the laboratory
data to a number of such computerized data sources
including Alberta Health and Wellness (AHW) adminis-
trative data, Alberta Bureau of Vital Statistics, the North-
ern and Southern Alberta Renal program databases [10],
as well as other databases related to program delivery such
as the Chronic Disease Management database. All data is
available electronically, thus there is no requirement for
manual data entry.
AHW administrative data includes all residents of the
province of Alberta, and contains data sources which per-
mit determination of disease incidence and prevalence
using validated algorithms for common medical condi-
tions such as hypertension, diabetes, acute myocardial
infarction, congestive heart failure and stroke [11-15], as
well as assessment of clinical, health outcomes and cost-
ing information. In addition to routine demographic
information and dates of death, the AHW Registry file
includes information to permit the assessment of Aborig-
inal [2], Chinese [16] and South Asian [17] ethnicity,
socio-economic status [18], and a six-digit postal code
which enables unique geographic information system
(GIS) analyses to be performed [19,20].
Alberta Blue Cross administers extended health benefits
paid by AHW on behalf of eligible individuals, including
residents aged 65 and older, for services which include
Data sources and variables linked to the Alberta Kidney Disease Network laboratory data Figure 1
Data sources and variables linked to the Alberta Kidney Disease Network laboratory data.
Alberta Health and Wellness
Alberta Vital Statistics
Date of death
Cause of death
Alberta Health & 
Wellness
Alberta Health and Wellness
Population Registry
Date of birth, gender, First 
Nation status, postal code, 
socioeconomic status by ﬁscal 
year
Alberta Health and Wellness
Alberta Blue Cross
Formulary drugs, date of 
dispensing, quantity dispensed
Cost
Alberta Health and Wellness
Ambulatory Care
Date, nature and location of 
service
Diagnostic and procedure 
codes (ICD-9-CM and ICD10-
CA)
Cost
Alberta Health and Wellness
Inpatient Encounters
Admission and discharge dates
Diagnostic and procedure 
codes (ICD-9-CM and ICD-10-
CA)
Case Mix Group
Costs
Alberta Health and Wellness
Physician Claims
Date and location of service
Diagnostic codes (ICD-9-CM)
Provider specialty
Costs
Alberta Renal Program Database
Identiﬁcation of patients with a kidney 
transplant, on dialysis therapy, or 
recipients of multidisciplinary renal care
Alberta Kidney Disease Network
Laboratory Data
Results of laboratory tests 
(creatinine,hemoglobin, 
hemoglobin A1c, potassium, lipid 
proﬁle, urine protein)
Unique identiﬁer allowing linkage 
with other data sources
Alberta Kidney 
Disease Network 
Database
Selected Examples of 
Data Use
Identiﬁcation of medical risk 
(lab data, diagnostic codes)
Identiﬁcation of non-medical 
risk (socioeconomic status, 
First Nations status, 
geographic location, 
physician and health care 
resource & program 
availability by postal code 
region)
Quantiﬁcation of utilization 
of appropriate /inappropriate 
physician, out-patient 
resources, in-patient 
encounters, and 
medications
Health care costs and 
resource utilization
Final health outcomes 
(death, hospitalization, new 
diagnosis)
Intermediate health 
outcomes (hemoglobin A1c, 
progression of kidney 
function, adherence to 
standards of care)
Chronic Disease Management
Identiﬁcation of patients receiving 
Chronic Disease Management careBMC Nephrology 2009, 10:30 http://www.biomedcentral.com/1471-2369/10/30
Page 5 of 7
(page number not for citation purposes)
formulary drugs, permitting evaluation of drug use and its
impact on outcomes [21,22]. Details regarding ambula-
tory care encounters including emergency department vis-
its are obtained from the ambulatory care file, while in-
patient hospitalization information (including diagnostic
and procedure codes using ICD-9-CM until March 31
2002 followed by ICD-10) is retrieved from the hospitali-
zation file. The physician claims file provides detailed
information on all physician encounters, including up to
3 ICD-9 diagnostic codes. The physician claims and hos-
pitalization files are used to define diabetes mellitus and
hypertension following validated algorithms [11,12],
with other comorbid conditions based on a validated cod-
ing algorithm for Charlson comorbidites using ICD-9-CM
and ICD-10 codes [23]. The presence of one or more diag-
nostic code in any position up to 3 years prior to study
entry is used for identification of comorbidities.
Follow-up and capture of outcomes of particular rele-
vance for the study of kidney disease, including dialysis
initiation or kidney transplantation, is possible by linkage
with the Northern and Southern Alberta Renal Program
databases [10]. These two programs collectively provide
care to all patients with end-stage renal disease in the
province. Information on end-stage renal disease status
from this clinical database is supplemented by identifying
additional long-term dialysis patients from administrative
data based on an algorithm for ICD-9-CM codes from
physician claims [24].
Technical Specifications
As outlined in Figure 1, the database consists of linked
individual components. The AKDN database operates in a
limited access computing environment with a single data-
base server for storage of the data located in Calgary. The
AKDN uses the Calgary Health Region server for data stor-
age which maintains security standards required for indi-
vidual patient level data. Currently the database operates
on a Windows operating system. All client computers are
personal computers with secure access. All personal iden-
tifiers are stripped from the database prior to their use for
research purposes to protect patient confidentiality.
Strengths and Limitations in Use of Laboratory Data for 
Research Purposes
Laboratory data can be used for case identification and for
assessment of disease control, including the use of hemo-
globin A1C among patients with diabetes, cholesterol lev-
els among patients at risk for cardiovascular disease, and
hemoglobin levels among patients with chronic diseases.
It can also be used to identify adverse outcomes related to
a treatment or procedure, such as the development of
hyperkalemia among patients initiating an angiotensin
converting enzyme inhibitor or angiotensin receptor
blocker medication. Importantly the serum creatinine
measurement can be used to estimate kidney function and
define chronic kidney disease, and thus can be used for
ongoing surveillance (defined as the ongoing systematic
and population-based collection of data).
Surveillance is important for the purposes of disease
detection, assessment of trends, identification of service
needs for program and policy development, and research.
Recently efforts have been directed towards enhanced sur-
veillance for specific chronic medical conditions, includ-
ing diabetes, cardiovascular disease, and chronic kidney
disease. However, the ability to implement a comprehen-
sive surveillance system is limited by the availability of
data, and sources currently used often include outcome
measures only (such as hospitalization or mortality), or
are limited by incomplete assessment of comorbidity. The
computerized laboratory data within the AKDN provides
the potential for both case identification and ongoing
monitoring of chronic medical conditions such as chronic
kidney disease (using the serum creatinine to estimate
glomerular filtration rate), and can be enhanced to obtain
an assessment of comorbidity through linkage with
administrative data.
Notwithstanding its strengths, there are important limita-
tions which must be recognized when using the AKDN
data. First, the use of laboratory data to define a study
cohort by definition will limit the study to subjects who
have sought medical care and had a laboratory test under-
taken. Although the reasons for measurement are
unknown and selected patients may differ from patients
without these measurements, this is unlikely to invalidate
study findings which are based upon a large proportion of
patients from the source population and reflect standard
clinical practices in a defined geographic location with
universal access to health care. Furthermore a cohort iden-
tified by laboratory-based case finding is easily general-
ized to primary care practice. Second, use of
administrative data limits access to certain clinical varia-
bles such as blood pressure control and lifestyle factors
(smoking, exercise and diet), which may be potential con-
founders. However other important confounders such as
diabetes, hypertension and the Charlson comorbidity
index are captured using the computerized data sources.
Utility and Discussion
The AKDN has used this database to gain a more in-depth
understand of chronic kidney disease at the community
level, including prevalence and progression of kidney dys-
function [6,25] and aspects of health care delivery for
chronic kidney disease [2,3]. Risk factor assessment has
also been examined, including the association between
drug use and progression of kidney dysfunction [21,22] asBMC Nephrology 2009, 10:30 http://www.biomedcentral.com/1471-2369/10/30
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well as the impact of anemia on patient outcomes [1].
Other research questions are being explored, including
the economic impact of population based screening for
chronic kidney disease, the long term outcomes for
patients with radio-contrast induced acute kidney injury,
and several studies exploring the association between res-
idence location and health outcomes. To date primary
users of the database have included both clinician
researchers and graduate students within the AKDN. We
are currently exploring options for external data requests,
which must take into account provincial privacy and secu-
rity laws.
Conclusion
The AKDN has developed a unique repository of labora-
tory data which can be used for health services and health
policy research. Although originally developed by neph-
rology researchers, the AKDN database includes informa-
tion on all patients who have obtained routine laboratory
investigations (not just those with kidney disease), and
therefore could also be used for the study of other chronic
medical conditions.
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